4564.T OncoTherapy Science JPX +9.09% to JPY 24.00 on 03 Apr 2026: volume surge signals clinical interest

The most active mover in small-cap healthcare on 03 Apr 2026 was OncoTherapy Science, Inc. (4564.T), which closed on the JPX at JPY 24.00, up 9.09% on very heavy volume. The spike pushed the share price to its session high of JPY 24.00 from an open of JPY 22.00, with volume at 194,375,600.00 shares versus an average of 44,237,776.00. This intraday move makes 4564.T stock a watchlist candidate for traders seeking event-driven biotech flows and gives investors a fresh reason to revisit the company’s clinical pipeline and balance sheet

4564.T stock intraday drivers and volume dynamics

Today’s price move for 4564.T stock was led by heavy trading rather than a public corporate announcement. The stock opened at JPY 22.00 and hit a high of JPY 24.00, a JPY 2.00 gain from the prior close of JPY 22.00. Volume of 194,375,600.00 shares was 3.32 times the average, signalling institutional or retail momentum. Reuters coverage of OncoTherapy’s filings and financials appears alongside heightened market interest source. Traders should note session range (JPY 22.00–24.00) and the year range (JPY 19.00–35.00) when sizing positions

Financials and valuation snapshot for 4564.T stock

OncoTherapy reports a market cap of JPY 7,560,159,178.00 and shares outstanding of 343,643,599.00. Key ratios: EPS -2.83, P/E -7.77, price-to-book 3.71, price-to-sales 9.64 and current ratio 8.51. Cash per share stands at JPY 6.06 and book value per share at JPY 5.93. The company’s revenue per share is JPY 2.17 and R&D to revenue is 65.79%, consistent with a development-stage biotech. These metrics frame 4564.T stock as cash-rich versus debt-light but loss-making, so valuation relies on pipeline milestones rather than recurring profits

Clinical pipeline catalysts that matter for 4564.T stock

OncoTherapy’s pipeline drives long-term upside potential. Key assets include OTS167 (MELK inhibitor) in Phase I/II, S-588410 in Phase III for esophageal cancer, and antibody programs such as OTSA101. A Phase III readout or positive regulatory update for S-588410 would be a material catalyst for 4564.T stock. Conversely, trial delays or negative safety data would pressure the share price. Investors should track clinical calendars and the company website for filings and disclosures company site

Technicals and trading patterns for 4564.T stock

Technical indicators show a mixed short-term bias. The RSI at 54.14 sits near neutral, MACD histogram modestly negative at -0.06, and ADX 24.70 suggests a developing trend. Price sits above the 50-day average (JPY 21.12) and roughly in line with the 200-day average (JPY 23.86). Bollinger Bands middle is JPY 21.80 and upper JPY 23.65, so the close at JPY 24.00 indicates a breakout above the short band. For traders, tight stop management is appropriate given a 6-month decline of -12.00% and one-year decline of -18.52%

Risks and sector context for 4564.T stock

OncoTherapy sits in the Healthcare sector on JPX where average P/E is around 23.50 for peers, and biotech volatility is high. Major risks: clinical trial failure, dilution from equity raises (weighted shares grew 22.73% in last fiscal period), and negative EPS (-2.83). Strengths include low leverage (debt-to-equity 0.00 to 0.01 range) and strong current ratio 8.51. Sector performance is muted year-to-date; a successful catalyst could re-rate 4564.T stock but downside is pronounced if pipeline milestones slip

Meyka AI rates 4564.T with a score out of 100 and forecast

Meyka AI rates 4564.T with a score out of 100: 65.76 / 100, Grade B, Suggestion HOLD. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, analyst inputs and forecasts. The platform notes a company rating of C- from a third-party snapshot dated 2026-04-02 that flagged valuation and profitability concerns. Meyka AI’s forecast model projects a yearly price of JPY 17.31, and a monthly figure of JPY 16.61. Versus today’s close of JPY 24.00, the yearly projection implies an estimated downside of -27.88%. Forecasts are model-based projections and not guarantees. For more on trading flow, see our Meyka stock page for 4564.T Meyka 4564.T

Final Thoughts

4564.T stock closed the JPX session at JPY 24.00 on 03 Apr 2026 after a 9.09% intraday gain and a volume spike to 194,375,600.00 shares. The move was driven by market interest in OncoTherapy’s clinical pipeline rather than a clear corporate announcement, making the stock attractive for event-driven traders and speculative healthcare investors. Fundamental strengths include JPY 6.06 cash per share and a strong current ratio, while persistent negative EPS (-2.83) and high price-to-sales (9.64) keep valuation risk elevated. Meyka AI rates the stock 65.76 / 100 (Grade B, HOLD) and projects a yearly target of JPY 17.31, implying -27.88% downside from the close. That forecast is a model output, not an investment guarantee. Short-term traders can trade the liquidity and momentum, while longer-term investors should wait for clinical clarity or durable revenue growth before increasing exposure. Meyka AI provides this AI-powered market analysis to help frame those decisions

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.